CN101437398A - 用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂 - Google Patents

用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂 Download PDF

Info

Publication number
CN101437398A
CN101437398A CNA2007800165996A CN200780016599A CN101437398A CN 101437398 A CN101437398 A CN 101437398A CN A2007800165996 A CNA2007800165996 A CN A2007800165996A CN 200780016599 A CN200780016599 A CN 200780016599A CN 101437398 A CN101437398 A CN 101437398A
Authority
CN
China
Prior art keywords
conh
och
tetrazolium
alkyl
conr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800165996A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·F·麦克尔罗伊
罗伯特·J·科尔瓦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenrin Discovery LLC
Original Assignee
Jenrin Discovery LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenrin Discovery LLC filed Critical Jenrin Discovery LLC
Publication of CN101437398A publication Critical patent/CN101437398A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800165996A 2006-03-10 2007-03-09 用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂 Pending CN101437398A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78148506P 2006-03-10 2006-03-10
US60/781,485 2006-03-10

Publications (1)

Publication Number Publication Date
CN101437398A true CN101437398A (zh) 2009-05-20

Family

ID=38510173

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800165996A Pending CN101437398A (zh) 2006-03-10 2007-03-09 用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂

Country Status (8)

Country Link
US (2) US7687481B2 (enExample)
EP (1) EP1993560B1 (enExample)
JP (1) JP4851546B2 (enExample)
CN (1) CN101437398A (enExample)
AT (1) ATE538650T1 (enExample)
AU (1) AU2007226673A1 (enExample)
CA (1) CA2647031A1 (enExample)
WO (1) WO2007106721A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212058A (zh) * 2011-04-14 2011-10-12 范如霖 “单一的复合药”：手性含氮杂环酯、合成法及其在制备低毒性cb1受体抑制剂中的应用
CN102260246A (zh) * 2010-05-28 2011-11-30 范如霖 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用
CN102603713A (zh) * 2011-01-25 2012-07-25 范如霖 手性cb1受体抑制剂、制备方法及其医学用途
WO2012151958A1 (zh) * 2011-05-12 2012-11-15 Fan Rulin 低毒性3-吡唑羧酸酰胺、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
CN103554025A (zh) * 2011-05-12 2014-02-05 范如霖 3-砒唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
CN111936485A (zh) * 2018-01-30 2020-11-13 Pi工业有限公司 新型邻氨基苯甲酰胺，其作为杀虫剂的用途及其制备方法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027135A1 (en) * 2004-09-06 2006-03-16 F. Hoffmann-La Roche Ag 4-aminomethyl benzamidine derivatives and their use as factor viiia inhibitors
EP2035389A1 (en) * 2006-06-20 2009-03-18 AstraZeneca AB Therapeutic agents
GB0622569D0 (en) * 2006-11-11 2006-12-20 7Tm Pharma As Cannabinoid receptor modulators
CN103145620A (zh) * 2006-12-18 2013-06-12 7Tm制药联合股份有限公司 Cb1受体调节剂
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
US7655685B2 (en) * 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
RU2392943C2 (ru) * 2007-11-22 2010-06-27 Людмила Александровна Орлова Способ разгрузочно-диетической терапии
JP2011506410A (ja) * 2007-12-10 2011-03-03 ７ティーエム ファーマ エイ／エス カンナビノイド受容体モジュレーター
KR20100098563A (ko) * 2007-12-18 2010-09-07 사노피-아벤티스 아제티딘 유도체, 그의 제법 및 치료에서의 그의 적용
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2280696B9 (en) * 2008-03-18 2015-12-09 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
ES2349838B1 (es) * 2009-05-04 2011-11-15 Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im Derivados de pirazol bivalentes como inhibidores de ingesta
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
BR112013012958A2 (pt) * 2010-11-24 2016-07-12 Univ Ohio State Res Found inibidores integrin ligado com quinase
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US9133128B2 (en) 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
WO2013014204A2 (en) 2011-07-26 2013-01-31 Sanofi 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
BR112013013490B1 (pt) 2011-09-30 2019-10-22 National Health Research Institutes compostos e composição farmacêutica
BR102012017421A2 (pt) 2012-07-13 2015-04-14 Proteimax Biotecnolgia Ltda Peptídeo, composicão farmacêutica, ligante de receptor cb, metodo para modular a funcao de receptor cb, uso, método para o tratamento de obesidade, e, método para promover a redução de peso estetica em um indivíduo
WO2015188073A1 (en) 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
BR112018011784A2 (pt) 2015-12-09 2018-12-04 Res Triangle Inst agonistas aprimorados do receptor de apelina (apj) e usos dos mesmos
EP3279197A1 (en) * 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
ES3032633T3 (en) 2016-10-12 2025-07-22 Res Triangle Inst Heterocyclic apelin receptor (apj) agonists and uses thereof
IL273868B2 (en) * 2016-10-13 2024-07-01 Proteimax Biotecnologia Ltda Use of a compound, synthetic intermediate, pharmaceutical composition, and neuromodulatory therapeutic method
KR101974414B1 (ko) * 2017-09-12 2019-05-02 주식회사 티에스디라이프사이언스 1h-피라졸-3-아마이드계 화합물 유도체를 포함하는 섬유증 예방 또는 치료용 조성물
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020148760A1 (en) 2019-01-15 2020-07-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cb1r receptor blockers with acyclic backbones
KR102707476B1 (ko) * 2021-01-28 2024-09-20 주식회사 파미노젠 피라졸-카르복스아미드 유도체 화합물 및 이의 용도
WO2024092205A1 (en) * 2022-10-27 2024-05-02 The Trustees Of Indiana University Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease
WO2025199092A1 (en) * 2024-03-20 2025-09-25 The Trustees Of Indiana University Ship1 modulators and methods of treatment and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
CN1950361A (zh) 2004-05-10 2007-04-18 霍夫曼-拉罗奇有限公司 用于治疗肥胖的吡咯或咪唑酰胺化合物
WO2006067443A1 (en) 2004-12-23 2006-06-29 Astrazeneca Ab Therapeutic agents
WO2006133926A1 (en) 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
WO2007046550A1 (en) 2005-10-21 2007-04-26 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
GB0622569D0 (en) 2006-11-11 2006-12-20 7Tm Pharma As Cannabinoid receptor modulators
WO2013003926A1 (pt) 2011-07-01 2013-01-10 Instituto De Pesquisas Tecnológicas Do Estado De São Paulo Processo de recuperação de liga lantanídeo-metal-metalóide em pó nanoparticulado com recuperação magnética e produto

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260246A (zh) * 2010-05-28 2011-11-30 范如霖 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用
CN102260246B (zh) * 2010-05-28 2014-08-13 范如霖 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用
CN102603713A (zh) * 2011-01-25 2012-07-25 范如霖 手性cb1受体抑制剂、制备方法及其医学用途
CN102603713B (zh) * 2011-01-25 2014-05-14 范如霖 手性cb1受体抑制剂、制备方法及其医学用途
CN102212058A (zh) * 2011-04-14 2011-10-12 范如霖 “单一的复合药”：手性含氮杂环酯、合成法及其在制备低毒性cb1受体抑制剂中的应用
CN102212058B (zh) * 2011-04-14 2014-04-02 范如霖 “单一的复合药”：手性含氮杂环酯、合成法及其在制备低毒性cb1受体抑制剂中的应用
WO2012151958A1 (zh) * 2011-05-12 2012-11-15 Fan Rulin 低毒性3-吡唑羧酸酰胺、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
CN103554025A (zh) * 2011-05-12 2014-02-05 范如霖 3-砒唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
CN103554025B (zh) * 2011-05-12 2016-08-10 范如霖 3-砒唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
CN111936485A (zh) * 2018-01-30 2020-11-13 Pi工业有限公司 新型邻氨基苯甲酰胺，其作为杀虫剂的用途及其制备方法

Also Published As

Publication number Publication date
ATE538650T1 (de) 2012-01-15
JP4851546B2 (ja) 2012-01-11
AU2007226673A1 (en) 2007-09-20
US8088798B2 (en) 2012-01-03
CA2647031A1 (en) 2007-09-20
JP2009529540A (ja) 2009-08-20
US7687481B2 (en) 2010-03-30
EP1993560A4 (en) 2010-06-02
US20070213302A1 (en) 2007-09-13
EP1993560A2 (en) 2008-11-26
WO2007106721A2 (en) 2007-09-20
EP1993560B1 (en) 2011-12-28
US20100144791A1 (en) 2010-06-10
WO2007106721A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
CN101437398A (zh) 用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂
CN101842013B (zh) 可用于治疗包括肥胖症和糖尿病的代谢疾患的大麻素受体拮抗剂/逆激动剂
CN102060809B (zh) 一种大黄酸衍生物及其制备和用途
ES2389569T3 (es) Antagonistas/agonistas inversos de receptores de cannabinoides
KR101855358B1 (ko) 골암통증에서의 시그마 리간드의 용도
JP5423675B2 (ja) アゾール化合物
CN101795569A (zh) 用于治疗肥胖的大麻素受体拮抗剂/逆激动剂
EP2435040A2 (en) N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
TW200911756A (en) Novel compounds
CN103906746A (zh) 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物
CN102652135A (zh) 脂肪酸酰胺水解酶的含氮杂环抑制剂
KR20160054547A (ko) 비스테로이드성 항염증 약물 및 시그마 리셉터 리간드 조합들
CN103068800A (zh) 作为趋化因子受体活性调节剂的哌啶基化合物
CN103547263A (zh) 对于治疗代谢性疾病，包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
JP2016516792A (ja) α−２アドレノレセプターおよびシグマレセプターリガンドの組み合わせ物
CN1989103A (zh) 作为nmda受体拮抗剂的吲哚－2－甲脒衍生物
AU2022241458A1 (en) Use of phenoxypropylamine compounds to treat depression
EP3362058B1 (en) 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN1989126A (zh) 新的杂环羧酸酰胺衍生物
KR20170096130A (ko) 골관절염에서 시그마 수용체 리간드의 용도
CN110372593A (zh) 大麻素受体拮抗剂/反向激动剂
WO2001055093A1 (en) N-arylhydrazide compounds and use thereof as drugs
US8088926B2 (en) Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity
KR102802861B1 (ko) Gpr6의 테트라하이드로피리도피라진 조절제
EP1957067A1 (en) Indolone compounds useful to treat cognitive impairment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090520